Thrombophilic states

Handbook of Clinical Neurology

Volumn 120, Issue , 2014, Pages 1061-1071

  Martinelli, Ida ^a   Passamonti, Serena Maria ^a   Bucciarelli, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiphospholipid antibodies; Antithrombin; Coagulation; Factor V Leiden; Homocysteine; Lipoprotein(a); Protein C; Protein S; Prothrombin G20210A

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; LIPOPROTEIN A; PROTEIN C; PROTEIN S;

ANTIPHOSPHOLIPID ANTIBODIES; ARTICLE; CEREBROVASCULAR ACCIDENT; COAGULATION; GENETICS; HUMAN; METABOLISM; PROTHROMBIN G20210A; THROMBOPHILIA;

ANTIPHOSPHOLIPID ANTIBODIES; ANTITHROMBIN; COAGULATION; FACTOR V LEIDEN; HOMOCYSTEINE; LIPOPROTEIN(A); PROTEIN C; PROTEIN S; PROTHROMBIN G20210A;

HUMANS; STROKE; THROMBOPHILIA;

EID: 84890828599     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4087-0.00071-1     Document Type: Chapter

References (98)

1. Anglés-Cano E., de La Pena Diaz A., Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001, 936:261-275.
2. APASS Investigators Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
3. Aznar J., Mira Y., Vaya A., et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 2004, 91:1031-1034.
4. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
5. Blohorn A., Guegan-Massardier E., Triquenot A., et al. Antiphospholipid antibodies in the acute phase of cerebral ischemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 2002, 13:156-162.
6. Boncoraglio G., Carriero M.R., Chiapparini L., et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol 2004, 11:405-409.
7. Brey R.L. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005, 20:105-112.
8. Brey R.L., Hart R.G., Sherman D.G., et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990, 40:1190-1196.
9. Brey R.L., Stallworth C.L., McGlasson D.L., et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002, 33:2396-2400.
10. Brouwer J.L., Veeger N.J., van der Schaaf W., et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005, 128:703-710.
11. Camerlingo M., Finazzi G., Casto L., et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991, 41:1371-1373.
12. Cantu C., Alonso E., Jara A., et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke 2004, 35:1790-1794.
13. Casas J.P., Hingorani A.D., Bautista L.E., et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004, 61:1652-1661.
14. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999, 81:165-176.
15. Charakida M., Besler C., Batuca J.R., et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009, 302:1210-1217.
16. Christopher R., Nagaraja D., Dixit N.S., et al. Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand 1999, 99:121-124.
17. Comp P.C., Esmon C.T. Recurrent venous thromboembolism in patients with partial deficiency of protein S. N Engl J Med 1984, 311:1525-1528.
18. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood 1997, 90:1-11.
19. Dahlbäck B. Protein S and the C4b-binding protein: components involved in the regulation of the protein C anticoagulation system. Thromb Haemost 1991, 66:49-61.
20. Dahlbäck B., Carlsson M., Svesson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993, 90:1004-1008.
21. Danesh J., Collins R., Peto R. Lipoprotein (a) and coronary heart disease: a meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
22. De Groot P.G., Lutters B., Derksen R.H., et al. Lupus anticoagulants and the risk of a first episode deep vein thrombosis. J Thromb Haemost 2005, 3:1993-1997.
23. de Moerloose P., Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007, 44:106-113.
24. De Stefano V., Leone G., Mastrangelo S., et al. Clinical manifestation and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994, 72:352-358.
25. De Stefano V., Finazzi G., Mannucci P.M. Inherited thrombophilia: pathogenesis, clinical syndrome and management. Blood 1996, 87:3531-3544.
26. deVeber G., Andrew M., Adams C. Cerebral sinousvenous thrombosis in children. N Engl J Med 2001, 345:417-423. for the Canadian Pediatric Ischemic Stroke Study Group.
27. den Heijer M., Koster T., Blom H.J., et al. Hyperhomocysteinemia as a risk factor for venous thromboembolism. N Engl J Med 1996, 334:759-762.
28. Dentali F., Gianni M., Crowther M.A., et al. Natural history of cerebral vein thrombosis: a systematic review. Blood 2006, 108:1129-1134.
29. Dentali F., Crowther M.A., Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006, 107:2766-2773.
30. Egeberg O. Inherited antithombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965, 13:516-530.
31. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010, 55:22160-22167.
32. Falcon C.R., Cattaneo M., Panzeri D., et al. High prevalence of hyperhomocysteinemia in patients with juvenile venous thromboembosis. Arterioscler Thromb 1994, 14:1080-1083.
33. Ferro J., Canhão P., Stam J., et al. Prognosis of cerebral vein and dural sinus thrombosis. Stroke 2004, 35:664-670. for the lSCVT Investigators.
34. Finazzi G., Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C, and protein S. Thromb Haemost 1994, 71:15-18.
35. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848-853.
36. Folsom A.R., Rosamond W.D., Shahar E., et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999, 100:736-742.
37. Fukudome K., Kurosawa S., Stearns-Kurosawa D.J., et al. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. Biol Chem 1996, 271:17491-17498.
38. Gadelha T., André C., Jucá, et al. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis 2005, 19:49-52.
39. Galli M., Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J 2003, 4:180-186.
40. Galli M., Luciani D., Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipids syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
41. Ginsburg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
42. Girolami A., Simioni P., Lazzaro A.R., et al. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemost 1989, 61:144-147.
43. Green D., Otoya J., Oriba H., et al. Protein S deficiency in middle-aged women with stroke. Neurology 1992, 42:1029-1033.
44. Griffin J.H., Evatt B., Zimmerman T., et al. Deficiency of congenital protein C in congenital thrombotic disease. J Clin Invest 1981, 68:1370-1373.
45. Gunther G., Junker R., Strater R., et al. Childhood Stroke Study Group. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke 2000, 31:2437-2441.
46. Hankey G.J., Eikelboom J.W., van Bockxmeer F.M., et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001, 32:1793-1799.
47. Harris E.N., Gharavi A.E., Hughes G.R.V. Antiphospholipid antibodies. Clin Rheum Dis 1985, 11:591-609.
48. Haywood S., Liesner R., Pindora S., et al. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child 2005, 90:402-405.
49. Israels S.J., Seshia S.S. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987, 111:562-564.
50. Johnson E.J., Prentice C.R.M., Parapia L.A. Premature arterial disease associated with familial antithrombin III deficiency. Thromb Haemost 1990, 63:13-15.
51. Juul K., Tybjaerg-Hansen A., Steffensen R., et al. Factor V Leiden: the Copenaghen City Heart Study and 2 meta-analyses. Blood 2002, 100:3-10.
52. Karttunen V., Hiltunen L., Rasi V., et al. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003, 14:261-268.
53. Kenet G., Waldman D., Lubetsky A., et al. Paediatric cerebral sinus vein thrombosis. A multi-center, case controlled study. Thromb Haemost 2004, 92:713-718.
54. Kenet G., Lütkhoff L.K., Albisetti M., et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010, 121:1838-1847.
55. Kim R.J., Becker R.C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003, 146:948-957.
56. Kisiel W. Human plasma protein C. Isolation, characterization and mechanism of activation by alpha-thrombin. J Clin Invest 1979, 64:761-769.
57. Knuiman M.W., Folsom A.R., Chambless L.E., et al. Association of hemostatic variables with MRI-detected cerebral abnormalities: the Atherosclerosis Risk in Communities Study. Neuroepidemiology 2001, 20:96-104.
58. Koster T., Rosendaal F.R., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993, 342:1503-1506.
59. Lane D.A., Caso R. Antithrombin: structure, genomic organization, function and inherited deficiency. The Molecular Biology of Coagulation. Baillière's Clinical Haematology 1989, 961. Baillière Tindall, London. E.G.D. Tuddenham (Ed.).
60. Lane D.A., Mannucci P.M., Bauer K.A., et al. Inherited thrombophilia: part 1. Thromb Haemost 1996, 76:651-662.
61. Lee M., Hong K.S., Chang S.C., et al. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention - a meta-analysis. Stroke 2010, 41:1205-1212.
62. Martinelli I., Mannucci P.M., De Stefano V., et al. Different risk of thrombosis in four coagulation defects associated with inheredited thrombophilia. A study of 150 families. Blood 1998, 92:2353-2358.
63. Martinelli I., Battaglioli T., Pedotti P., et al. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003, 102:1363-1366.
64. Martinelli I., Bucciarelli P., Passamonti S.M., et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010, 121:2740-2746.
65. Mercuri E., Cowan F., Gupte G., et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001, 107:1400-1404.
66. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipide syndrome (APS). J Thromb Haemost 2006, 4:295-306.
67. Naess I.A., Christiansen S.C., Cannegieter S.C., et al. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006, 4:44-49.
68. Nencini P., Baruffi M.C., Abbate R., et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992, 23:189-193.
69. Nowak-Göttl U., Junker R., Hartmeier M., et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999, 100:743-748.
70. Nowak-Göttl U., Kurnik K., Krumpel A., et al. Thrombophilia in the young. Hamostaseologie 2008, 20:16-20.
71. Ortel T.L. Genetics of coagulation disorders. Genetics of Cerebrovascular Disease 1999, 129-156. Futura Publishing, Armonk, NY. M.J. Alberts (Ed.).
72. Pezzini A., Del Zotto E., Magoni M., et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent forame ovale. Stroke 2003, 34:28-33.
73. Poort S.R., Rosendaal F.R., Reitsma P.M., et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
74. Pruissen D.M.O., Slooter A.J.C., Rosendaal F.R., et al. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008, 111:1282-1286.
75. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet 1995, 346:1133-1134.
76. Rosendaal F.R. Risk factor for venous thromboembolism. Thromb Haemost 1999, 82:610-619.
77. Rosendaal F.R., Koster T., Vandenbroucke J.P., et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995, 85:1504-1508.
78. Rosendaal F.R., Doggen C.J.M., Zivelin A., et al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 1998, 79:706-709.
79. Rubattu S., Di Angelantonio E., Nitsch D., et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost 2005, 93:1095-1100.
80. Runchey S.S., Folsom A.R., Tsa M.Y., et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002, 119:1005-1010.
81. Sacco R.L., Owen J., Mohr J.P., et al. Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke 1989, 20:1657-1661.
82. Sastry S., Riding G., Morris J., et al. Young Adult Myocardial Infarction and Ischemic Stroke: the role of paradoxical embolism and thrombophilia (The YAMIS Study). J Am Coll Cardiol 2006, 48:686-691.
83. Smith N.L., Bis J.C., Biagiotti S., et al. Variation in 24 hemostatic genes and associations with non-fatal myocardial infarction and ischemic stroke. J Thromb Haemost 2008, 6:45-53.
84. Smolders B., Lemmens R., Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007, 38:1959-1966.
85. Stam J. Thrombosis of the cerebral vein and sinuses. N Engl J Med 2005, 352:1791-1798.
86. Strater R., Becker S., von Eckardstein A., et al. Prospective assessment of risk factors for recurrent stroke during childood - a 5-year follow-up study. Lancet 2002, 360:1540-1545.
87. Tait R.C., Walker I.D., Perry D.J., et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994, 87:106-111.
88. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995, 73:87-93.
89. Toschi V., Motta A., Castelli C., et al. High prevalence of antiphospholipid antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998, 29:1759-1764.
90. Ueyama H., Hashimoto Y., Uchino M. Progressing ischemic stroke in a homozygote with variant antithrombin III. Stroke 1989, 20:815-818.
91. Urbanus R.T., Derksen R.H., de Groot P.G. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev 2008, 22:93-105.
92. Ventura P., Cobelli M., Marietta M., et al. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis 2004, 17:153-159.
93. Vomberg P.P., Breederveld C., Fleury P. Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics 1987, 18:42-44.
94. Voorberg J., Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with a single point-mutation at Arg506 of factor V. Lancet 1994, 343:1535-1536.
95. Wahl D.G., Guillemin F., de Maistre E., et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998, 7:15-22.
96. Wasay M., Bakshi R., Bobustuc G., et al. Cerebral venous thrombosis: analysis of a multicentre cohort from the United States. J Stroke Cerebrovascular Dis 2008, 17:49-54.
97. Wilson W.A., Gharavi A.E., Koile T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
98. Young G., Albisetti M., Boundel M., et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 2008, 118:1373-1382.